Results 21 to 30 of about 151,271 (335)

Benign prostatic hyperplasia : Part 1- diagnosis [PDF]

, 2008
Peer reviewedPublisher ...
N'Dow, James Michael Olu, Wilt, Timothy
core   +2 more sources

Comparative application of testosterone undecanoate and/or testosterone propionate in induction of benign prostatic hyperplasia in Wistar rats.

PLoS ONE, 2022
Testosterone undecanoate is a hormone agent with long-acting potential and is used for testosterone replacement therapy for hypogonadism. This study was designed to investigate application of testosterone undecanoate in maintaining high androgen levels ...
Jinho An, Hyunseok Kong
doaj   +1 more source

Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review

International journal of urology, 2021
Benign prostatic hyperplasia is a major disease that affects the quality of life of middle‐aged and older men. Although >70% of men aged >70 years have pathological benign prostatic hyperplasia, its pathogenesis and progression remain unclear.
H. Tsunemori, M. Sugimoto
semanticscholar   +1 more source

Interstitial laser therapy of benign prostatic hyperplasia [PDF]

, 1999
The objective of interstitial laser coagulation (ILC) of benign prostatic enlargement is to achieve a marked volume reduction and to decrease bladder outlet obstruction and lower urinary tract symptoms with minimal morbidity.
Muschter, Rolf, Whitfield, Hugh
core   +1 more source

Role of gangliosides in prostate pathology [PDF]

Romanian Journal of Infectious Diseases, 2016
Molecular pathology of benign prostatic hyperplasia is multifactorial and involves endocrine, biochemical, immunological interactions. The mechanisms involved in the onset and progression of benign prostatic hyperplasia are: infections, 50 years of age ...
Ilinca Nicolae, Corina-Daniela Ene, Simona Roxana Georgescu   +2 more
doaj   +1 more source

Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle. [PDF]

, 2012
The transcription factors Elk1 and serum response factor (SRF) are central regulators of cell cycle and phenotype in various cell types. Elk1 is activated by phosphorylation (serine-383), while activation of SRF requires its co-factor, myocardin ...
Andersson, Karl-Erik, Beckmann, Christer, Füllhase, Claudius, Gratzke, Christian, Hedlund, Petter, Hennenberg, Martin, Montorsi, Francesco, Rutz, Beata, Stief, Christian Georg, Strittmatter, Frank, Waidelich, Raphaela   +10 more
core   +2 more sources

Studies on Chromatographic Fingerprint and Fingerprinting Profile-Efficacy Relationship of Saxifraga stolonifera Meerb.

Molecules, 2015
This work investigated the spectrum-effect relationships between high performance liquid chromatography (HPLC) fingerprints and the anti-benign prostatic hyperplasia activities of aqueous extracts from Saxifraga stolonifera.
Xing-Dong Wu, Hua-Guo Chen, Xin Zhou, Ya Huang, En-Ming Hu, Zheng-Meng Jiang, Chao Zhao, Xiao-Jian Gong, Qing-Fang Deng   +8 more
doaj   +1 more source

Coupling of alpha(1)-Adrenoceptors to ERK1/2 in the Human Prostate [PDF]

, 2011
Introduction: alpha(1)-Adrenoceptors are considered critical for the regulation of prostatic smooth muscle tone. However, previous studies suggested further alpha(1)-adrenoceptor functions besides contraction.
Anglin IE, Boris Schlenker, Chang L, Chon JK, Christ GJ, Christian G. Stief, Christian Gratzke, Erdogru T, Frank Strittmatter, Glassman DT, Golomb E, Johanna Göttinger, Kanagawa K, Karl-Erik Andersson, Kyprianou N, Kyprianou N, Kyprianou N, Lucia MS, Luthin GR, Marinese D, Maroni PD, Martin Hennenberg, McCubrey JA, McVary KT, Michel MC, Oliver Reich, Petter Hedlund, Ricarda M. Bauer, Roehrborn CG, Roehrborn CG, Royuela M, Royuela M, Schilit S, Schwinn DA, Shimada K, Srinivasan D, Turkeri LN, Xiao L, Zhang H, Zhang Z   +39 more
core   +1 more source

Quantitation of α_1A and α_1D-adrenoceptor mRNA in prostate tissues from patients with symptomatic benign prostatic hyperplasia

Journal of Pathology of Nepal, 2011
Background: To treat symptomatic benign prostatic hyperplasia α1-adrenoceptor antagonists with little antagonism at α1b-adrenoceptor were used to avoid orthostatic hypotension.
B Acharya, H Okada, G Aryal, T Shirakawa, N Hinata, A Gotoh   +5 more
doaj   +1 more source

Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes

Nature Communications, 2020
Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, is among the most common diseases affecting aging men, but the underlying molecular features remain poorly understood, and therapeutic options are limited.
Deli Liu, J. Shoag, D. Poliak, R. Goueli, Vaishali Ravikumar, D. Redmond, A. Vosoughi, J. Fontugne, H. Pan, Daniel J. Lee, Domonique Thomas, K. Salari, Zongwei Wang, A. Romanel, A. Te, R. Lee, B. Chughtai, A. Olumi, J. Mosquera, F. Demichelis, O. Elemento, M. Rubin, A. Sboner, C. Barbieri   +23 more
semanticscholar   +1 more source